Tracing a cancer Drug's journey through the body

NCT ID NCT07643870

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug in blood, urine, and stool to understand its absorption and elimination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD1390
What this could lead to: If successful, this study will show how AZD1390 is processed by the body, which could help design better dosing for future trials.
What could go wrong: This is a very early, small study focused on drug behavior, not treatment effect. It may not lead to any direct benefit for participants or future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer glioblastoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES

Contacts and locations

Locations

Research Site

Guildford, GU2 7WG, United Kingdom
Research Site

Liverpool, L7 8XP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.